Gilead Sciences Inc. (GILD: Quote) has gapped open sharply higher Thursday morning and is now up 4.07 at $57.70. The stock has broken out past resistance and has set a new high for the year.
Bristol-Myers Squibb (BMY: Quote) announced after the bell Wednesday that it has suspended study drug administration in an ongoing Phase II study of BMS-986094, a nucleotide polymerase inhibitor in development for the treatment of hepatitis C.
Click here to receive FREE breaking news email alerts for Gilead Sciences Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org